For women with a specific type of breast cancer known as HER2-positive (HER2+), any residual (leftover) disease after primary ...

SAN ANTONIO — Nice try, ATEMPT investigators, but trastuzumab emtansine (T-DM1) does not have a disease-free survival or safety advantage over paclitaxel plus trastuzumab in the adjuvant setting for ...

PDT 9 (29.0) 13.0 to 45.0 TR 4 (12.9) 1.1 to 24.7 AB 10 (32.3) 15.8 to 48.8 Abbreviations: AB, any benefit; ER, estrogen receptor; PDT, prolonged duration on therapy; PR, progesterone receptor; T-DM1, ...

SAN ANTONIO -- Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib ...

Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening In the article that accompanies this editorial, Dzimitrowicz et al 10 provide a real-world glimpse of T-DM1 in patients who ...

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Among patients with previously treated HER-2–positive locally advanced or metastatic gastric or ...

ZURICH (Reuters) - Roche said patients with an aggressive type of breast cancer lived longer after taking its experimental "armed antibody" drug without the disease worsening than those on a mix of ...

Investigational drug linked to Herceptin promising in clinical trials. June 3, 2012— -- For Bridget Spence, graduation from college was a short-lived joy. Just one week after receiving her degree ...

Patient undergoing chemotherapy. Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.

August 28, 2012 — A novel twist on the targeted agent trastuzumab (Herceptin, Genentech/Roche), known as trastuzumab emtansine (or T-DM1), is a step closer to market. Updated results from a pivotal ...